sevoflurane anesthetics

PreclinicalSmall molecule

YYonsei University

sevoflurane anesthetics is one of 7 small molecule programs targeting Biliary Atresia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary AtresiaActive, not recruiting

Biliary AtresiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Biliary Atresia

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Acetadote

AArbor Pharmaceuticals, Inc.

Bylvay

2 4

Mycifradin

PPharmacia and Upjohn

Preclinical

1 5

sevoflurane anesthetics

YYonsei University

Preclinical

1 6

Lactobacillus Casei Rhamnosus (lcr35)

NNational Taiwan University Hospital

Preclinical

1 7

Propanolol

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Biliary Atresia1 trial

The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation

Completed·YYonsei University·N/A·NCT01443572·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sevoflurane anesthetics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sevoflurane anesthetics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sevoflurane anesthetics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

sevoflurane anesthetics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Biliary Atresia1 trial

References

Drug Info

Quick Facts

Related News